Convalescent Plasma Decision May Be ‘Week Or Two’ Away, US FDA’s Hahn Says
Executive Summary
Commissioner says the agency is reviewing efficacy and safety data, presumably for an emergency use authorization of a product derived from patients who recovered from the virus.